{
    "root": "3016dda9-70dc-791c-e063-6294a90a868f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Finasteride",
    "value": "20250311",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "DOCUSATE SODIUM",
            "code": "F05Q2T2JA0"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FINASTERIDE",
            "code": "57GNO57U7G"
        }
    ],
    "indications": "finasteride tablets , 5α-reductase inhibitor , indicated treatment symptomatic benign prostatic hyperplasia ( bph ) men enlarged prostate ( 1.1 ) : • improve symptoms • reduce risk acute urinary retention • reduce risk need surgery including transurethral resection prostate ( turp ) prostatectomy . finasteride tablets usp administered combination alpha-blocker doxazosin indicated reduce risk symptomatic progression bph ( confirmed ≥4 point increase american urological association ( aua ) symptom score ) ( 1.2 ) . limitations : finasteride tablets usp approved prevention prostate cancer ( 1.3 ) . ( 1 )",
    "contraindications": "finasteride tablets may administered without meals .",
    "warningsAndPrecautions": "finasteride tablets usp , 5 mg blue color , round film coated tablets , debossed ‘ h ’ one side ‘ 37 ’ sideon side . supplied follows : unit bottles 30 : 5 mg ( ndc 68645-541-54 ) storage handling store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . protect light keep container tightly closed . females handle crushed broken finasteride tablets usp pregnant may potentially pregnant possibility absorption finasteride subsequent potential risk male fetus [ ( 5.3 ) , ( 8.1 ) ] . distributed : wal-mart bentonville , ar 72716 packaged : legacy pharmaceutical packaging llc earth city , mo 63045",
    "adverseReactions": "finasteride tablets contraindicated following : • hypersensitivity component medication . • pregnancy . finasteride contraindicated females may potentially pregnant . ability type ii 5α-reductase inhibitors inhibit conversion testosterone 5α-dihydrotestosterone ( dht ) , finasteride may cause abnormalities external genitalia male fetus pregnant female receives finasteride . used pregnancy , pregnancy occurs taking , pregnant female apprised potential hazard male fetus . [ also ( 5.3 ) , ( 8.1 ) , supplied/storage handling ( 16 ) patient counseling information ( 17.2 ) . ] female rats , low doses finasteride administered pregnancy produced abnormalities external genitalia male offspring .",
    "indications_original": "Finasteride tablets, are a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( 1.1 ): • Improve symptoms • Reduce the risk of acute urinary retention • Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Finasteride tablets USP administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association(AUA) symptom score) ( 1.2 ). Limitations of Use: Finasteride tablets USP is not approved for the prevention of prostate cancer ( 1.3 ). (1)",
    "contraindications_original": "Finasteride tablets may be administered with or without meals.",
    "warningsAndPrecautions_original": "Finasteride tablets USP, 5 mg are blue color, round film coated tablets, debossed with ‘H’ on one side ‘37’ on other sideon other side. They are supplied as follows:\n  \n                     \nUnit of Use Bottles of 30: 5 mg (NDC 68645-541-54)\n  \n                     \n                     \n                     \n                     Storage and Handling \n                     \n                     \n                     \n                     \nStore at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and keep container tightly closed.\n  \n                     \n                     \n                     \nFemales should not handle crushed or broken finasteride tablets USP when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus \n   [see \n   Warnings and Precautions (5.3), and \n   Use in Specific Populations (8.1) ]. \n  \n                  \n                  \n                  \n                     Distributed by: \n                     \nWal-Mart\n  \nBentonville, AR 72716\n \n                  \n                  \n                     Packaged by: \n                     \nLegacy Pharmaceutical Packaging LLC\n  \nEarth City, MO 63045",
    "adverseReactions_original": "Finasteride tablets are contraindicated in the following:\n  \n                     \n• Hypersensitivity to any component of this medication.\n  \n                     \n• Pregnancy. Finasteride use is contraindicated in females when they are or may potentially be pregnant. Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant female should be apprised of the potential hazard to the male fetus. \n  [See also \n                     \n                        Warnings and Precautions (5.3)\n                     \n                     , \n                     \n                        Use in Specific Populations (8.1)\n                     \n                     , \n                     \n                        How Supplied/Storage and Handling (16)\n                     \n                     and \n                     \n                        Patient Counseling Information (17.2)\n                     \n                     .] In female rats, low doses of finasteride administered during pregnancy have produced abnormalities of the external genitalia in male offspring."
}